INTRODUCTION In the past few years many trials have evaluated the use of maintenance therapy in the treatment of NSCLC stage IV. Both switch as well as continuation maintenance show an improved PFS and overall survival. HRQoL data was only partially published. The aim of this article is to review the published effects of maintenance therapy on HRQoL. METHODS Two PubMed searches were performed...

Numerous studies have been done on using low serum lithium levels for maintenance therapy of bipolar mood disorder over the past 30-40 years. In this study we sought for the most suitable serum lithium level that having longer relapse's interval periods and less side effects as to recommended it as a maintenance serum lithium level. Thus, we studied 90 patients with bipolar mood disorder (accor...

Maintenance therapy has emerged as a novel therapeutic paradigm for advanced non-small-cell lung cancer (NSCLC). Maintenance therapy that aims to sustain a clinically favorable state after first-line chemotherapy has two strategies. Switch maintenance therapy entails switching to a new and non-cross-resistant agent in an alternating or sequential manner, on completion of first-line chemotherapy...

background: the retention rates are important factors in methadone maintenance treatment. this study was performed with aims to determine the attitude and subjective norms in methadone treatment maintenance among kohgilouyeh and boyer ahmad’s province addict who referred addiction treatment centers. methods: this research was a cross-sectional study that done among men’s addicted who are receiv...

Maintenance therapy has become quite a hot topic for those of us working in the field of solid tumor malignancies. Our original concept of chemotherapy for solid tumors was to give a certain number of cycles and then stop treatment, or to continue treatment until an intolerable toxicity arose. Given that we now have more management tools at our disposal, and as treatments given chronically have...

The treatment of multiple myeloma (MM) has changed dramatically in the past twenty years with the introduction of high-dose therapy plus autologous stem-cell transplantation (ASCT) in younger patients and, more recently, of three novel agents (thalidomide, bortezomib, and lenalidomide). When conventional chemotherapy was the only available possibility, complete responses (CR) were very rare and...